Enfortumab Vedotin‐Related Skin Toxicities: Insights From Clinical and Histopathological Analysis
Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.
Authors
- Masatoshi Eto (ORCID: https://orcid.org/0000-0002-3312-9930)
- Yoko Fuyuno (ORCID: https://orcid.org/0000-0002-6209-7923)
- Makiko Kido‐Nakahara (ORCID: https://orcid.org/0000-0002-4169-1309)
- Yoshinao Oda (ORCID: https://orcid.org/0000-0001-9636-1182)
- Takeshi Nakahara (ORCID: https://orcid.org/0000-0003-2811-8273)
- Yuki Kuma (ORCID: https://orcid.org/0000-0002-5131-5585)
- Takashi Matsumoto (ORCID: https://orcid.org/0000-0002-6603-9181)
Institutions
- Kyushu University (JP)
Publication Details
- Journal
- The Journal of Dermatology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1111/1346-8138.17901
- Citations
- 3
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.41